Aytu Biopharma Inc Quick Ratio (AYTU) starting from the fourth quarter 2026 to fourth quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Aytu Biopharma Inc  (NASDAQ: AYTU)

Aytu Biopharma Inc's Quick Ratio

AYTU's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Current Liabilities decreased faster than Aytu Biopharma Inc's Cash & cash equivalent, this led to improvement in Aytu Biopharma Inc's Quick Ratio to 0.48, Quick Ratio remained below Aytu Biopharma Inc average.

Within Major Pharmaceutical Preparations industry 394 other companies have achieved higher Quick Ratio than Aytu Biopharma Inc in fourth quarter 2026. While Quick Ratio total ranking in the fourth quarter 2026 has deteriorated compared to the prior quarter from 2388 to 2668.

Explain Quick Ratio?
How much Cash & cash equivalents AYTU´s has?
What are AYTU´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

AYTU Quick Ratio (Jun 30 2026)
Q4		 (Mar 31 2026)
Q3		 (Dec 31 2025)
Q2		 (Sep 30 2025)
Q1		 (Jun 30 2025)
Q4
Y / Y Current Liabilities Change -13.33 % -15.18 % 1.34 % 7.74 % 3.14 %
Y / Y Cash & cash equivalent Change -15 % 47 % 54.71 % 62.27 % 54.71 %
Quick Ratio MRQ 0.48 0.45 0.49 0.49 0.49
AYTU's Total Ranking # 2668 # 2388 # 521 # 2145 # 2004
Seq. Current Liabilities Change -8.86 % -4.9 % -4.44 % 4.64 % -10.81 %
Seq. Cash & cash equivalent Change -1.52 % -13.69 % -5.14 % 5.42 % 70.32 %



Quick Ratio fourth quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 395
Healthcare Sector # 747
Overall Market # 2668


Quick Ratio Statistics
High Average Low
8.67 1.22 0
(Sep 30 2015)   (Feb 28 2014)




Financial Statements
Aytu Biopharma Inc's Current Liabilities $ 55 Millions Visit AYTU's Balance sheet
Aytu Biopharma Inc's Cash & cash equivalent $ 26 Millions Visit AYTU's Balance sheet
Source of AYTU's Sales Visit AYTU's Sales by Geography


Cumulative Aytu Biopharma Inc's Quick Ratio

AYTU's Quick Ratio for the trailling 12 Months

AYTU Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth -5.27 % -1.27 % -2.05 % -4.77 % -7.9 %
Y / Y Cash & cash equivalent TTM Growth 30.67 % 54.87 % 41.1 % 22.81 % 7.89 %
Quick Ratio TTM 0.48 0.48 0.43 0.39 0.35
Total Ranking TTM # 4046 # 4059 # 835 # 3268 # 3128
Seq. Current Liabilities TTM Growth -3.33 % -4.08 % 0.32 % 1.84 % 0.75 %
Seq. Cash & cash equivalent TTM Growth -3.83 % 7.58 % 10.76 % 14.03 % 13.98 %

Quick ratio ranking by company, industry and sector >> Back to AYTU Financial Strength Comparisons >> Go to Compare AYTU Quick Ratio to its Competitors

On the trailing twelve months basis In spite of the year on year decrease in AYTU's Current Liabilities to $54.66 millions, cumulative Quick Ratio to 0.48 below the AYTU average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 438 other companies have achieved higher Quick Ratio than Aytu Biopharma Inc. While Quick Ratio overall ranking has improved so far to 4046, from total ranking during the twelve months ending third quarter 2026 at 4059.

Explain Quick Ratio?
How much Cash & cash equivalents AYTU´s has?
What are AYTU´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 439
Healthcare Sector # 902
Within the Market # 4046


trailing twelve months Quick Ratio Statistics
High Average Low
4 0.87 0.01
(Mar 31 2016)   (Mar 31 2014)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Cormedix Inc   1.31 $ 256.692  Millions$ 196.535  Millions
Transcode Therapeutics Inc   1.30 $ 8.383  Millions$ 6.430  Millions
Elite Pharmaceuticals Inc   1.28 $ 39.032  Millions$ 30.442  Millions
Ani Pharmaceuticals Inc  1.27 $ 360.212  Millions$ 283.655  Millions
Pmgc Holdings Inc   1.25 $ 19.126  Millions$ 15.329  Millions
Petros Pharmaceuticals inc   1.23 $ 3.489  Millions$ 2.845  Millions
Nature s Sunshine Products inc   1.20 $ 82.503  Millions$ 68.745  Millions
Phathom Pharmaceuticals Inc   1.19 $ 182.478  Millions$ 153.777  Millions
Compass Pathways Plc  1.18 $ 433.720  Millions$ 367.285  Millions
Geovax Labs Inc   1.17 $ 3.163  Millions$ 2.712  Millions
Actuate Therapeutics Inc   1.16 $ 4.426  Millions$ 3.805  Millions
Apimeds Pharmaceuticals US, Inc.  1.16 $ 8.278  Millions$ 7.166  Millions
Emergent Biosolutions Inc   1.14 $ 139.700  Millions$ 122.800  Millions
Turn Therapeutics Inc   1.14 $ 9.958  Millions$ 8.764  Millions
Ionis Pharmaceuticals Inc   1.11 $ 350.065  Millions$ 315.638  Millions
Oramed Pharmaceuticals Inc  1.00 $ 16.091  Millions$ 16.044  Millions
Inmed Pharmaceuticals Inc  1.00 $ 2.240  Millions$ 2.235  Millions
Nkarta Inc   1.00 $ 24.958  Millions$ 24.924  Millions
Inovio Pharmaceuticals Inc   1.00 $ 36.700  Millions$ 36.678  Millions
Jazz Pharmaceuticals Plc  0.98 $ 2,199.800  Millions$ 2,239.400  Millions
Akebia Therapeutics Inc   0.97 $ 155.548  Millions$ 160.865  Millions
Syndax Pharmaceuticals Inc   0.95 $ 342.883  Millions$ 360.284  Millions
Nurix Therapeutics Inc   0.94 $ 67.840  Millions$ 72.020  Millions
Theriva Biologics inc   0.94 $ 11.337  Millions$ 12.111  Millions
Geron Corporation  0.92 $ 64.781  Millions$ 70.331  Millions
Zomedica Corp   0.84 $ 7.605  Millions$ 9.002  Millions
Cocrystal Pharma Inc   0.83 $ 2.169  Millions$ 2.616  Millions
Harrow Inc   0.82 $ 83.889  Millions$ 102.171  Millions
Cue Biopharma Inc   0.82 $ 17.414  Millions$ 21.218  Millions
Zoetis Inc   0.81 $ 1,676.000  Millions$ 2,061.000  Millions

Date modified: 2026-09-26T08:02:23+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.